# An Expanded Access Program for AM0010 (Pegilodecakin)

> **NCT03554434** · — · NO_LONGER_AVAILABLE · sponsor: **Eli Lilly and Company**

## Conditions studied

- Melanoma
- Prostate Cancer
- Ovarian Cancer
- Renal Cell Carcinoma
- Colorectal Carcinoma
- Pancreatic Carcinoma
- Non-small Cell Lung Carcinoma
- Solid Tumors
- Breast Cancer

## Interventions

- **BIOLOGICAL:** AM0010

## Key facts

- **NCT ID:** NCT03554434
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2020-03-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03554434

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03554434, "An Expanded Access Program for AM0010 (Pegilodecakin)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03554434. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*